Advertisement
Evidence presented virtually to a global audience at the annual congress of the European Society for Medical Oncology (ESMO), suggests that a third ”booster” shot could further increase the level of protection among this patient population.
Patients with cancer were excluded from the clinical trials conducted to develop the COVID-19 vaccines and support their authorization for use.
The questions of whether the vaccines are safe in this vulnerable population and whether they provide adequate protection against severe forms of COVID-19 to individuals whose immune system may be weakened by various anticancer medicines had until now been left open.
Related Articles
Advertisement
The researchers enrolled 791 patients from multiple hospitals in the Netherlands in four distinct study groups to measure their responses to Moderna’s two-dose vaccine.
The participants comprised individuals without cancer, patients with cancer treated with immunotherapy, patients treated with chemotherapy, and those treated with a chemo-immunotherapy combination.
At 28 days after administration of the second dose, adequate levels of antibodies to the virus in the blood were found in 84 percent of patients receiving chemotherapy, 89 percent of patients receiving chemo-immunotherapy and 93 percent of patients on immunotherapy alone.
Antonio Passaro, a lung cancer expert at the European Institute of Oncology in Italy, who was not involved in the study, said these results compare favorably with the antibody responses seen in almost all (99.6 percent) of the group of individuals without cancer.
“The high rates of the efficacy of the vaccine observed across the trial population, regardless of the type of anticancer treatment, constitute a strong and reassuring message for patients and their doctors,” Passaro said in a statement.
He highlighted the importance of ensuring complete, two-dose vaccination for patients with cancer to develop enough protective antibodies against the virus.
The trial data also showed that only about one in three of those receiving chemotherapy on its own or in combination with immunotherapy had achieved a sufficient response after their first shot — half as many as in the group of individuals without cancer. This observation was replicated in a second study on the effects of the Pfizer vaccine among 232 patients with cancer and 261 control subjects in Israel.
While less than a third of individuals with cancer developed antibodies after receiving the first dose, compared to 84 per cent in the control group, this proportion increased to 86 percent following administration of the second dose.
Further demonstrating the efficacy of the vaccine, only two cases of COVID-19 were reported during the study period, both of which occurred in patients who had not yet received their second shot.
Data from another study was presented at the conference that was conducted on 585 patients with cancer who received two doses of either Pfizer or AstraZeneca’s COVID-19 Vaccine in the UK.
Those who had previously contracted COVID-19 (31 percent) had higher levels of virus-neutralizing antibodies, including against variants such as Delta, for which vaccination loses some of its effectiveness.
This was separately corroborated by a fourth study which showed that the antibody response to vaccination was significantly enhanced even after the first dose among patients with cancer who had recovered from COVID-19.
“These findings lend additional support to the principle of offering the complete cycle, possibly including a third booster dose, to patients with cancer to improve their protection,” Luis Castelo-Branco, Medical Oncologist, ESMO Scientific and Medical Division, said.
According to Castelo-Branco, these and other studies presented at the conference reported no new adverse events, and offer conclusive evidence that while being largely effective, anti-COVID vaccination is just as safe for people with cancer as it is for the general population.